Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers

Jiang, Ji and Li, Lilly and Yin, Hequn and Woessner, Ralph and Emotte, Corinne and Li, Ruobing and Khindri, Sanjeev and Hu, Pei (2014) Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 40 (2). pp. 203-208. ISSN 2107-0180

Abstract

Indacaterol is an inhaled, ultra-long-acting β2-agonist that provides 24-h bronchodilation with once-daily dosing in patients with chronic obstructive pulmonary disorder. This study evaluated the pharmacokinetics, safety, and tolerability of multiple daily inhaled doses of indacaterol 150 or 300 μg once daily in healthy Chinese volunteers. This was a single-center, randomized, double-blind, multiple-dose, parallel-group study, placebo-controlled trial including two doses of indacaterol: 150 and 300 μg. Serum indacaterol was quantified using high-performance liquid chromatography-mass spectrometry with a lower limit of quantification of 0.01 ng/mL. The pharmacokinetic parameters were analyzed using non-compartmental analysis and included Cmax, Tmax, and AUC0-24h on Day 1 and AUC0-24h,ss, Cmax,ss, Cmin,ss, Cav,ss, Tmax,ss, T1/2, T1/2,acc, CL/F, Vz/F, and Racc on Day 14 (after repeated once-daily doses). Safety analyses were recorded using physical examination, biochemical tests, and ECG. Indacaterol steady state was achieved after 12-14 days of daily dosing. The mean effective half-life of indacaterol (based on drug accumulation at steady state) was 33.9 and 35.8 h for 150 and 300 μg, respectively. Systemic exposure to indacaterol increased 1.27 and 1.34-fold between the 150- and 300-μg doses on Day 1 (first dose) and Day 14 (repeated dose), respectively. Indacaterol 150 and 300 μg were safe and well tolerated in these volunteers. The pharmacokinetics of multiple inhaled doses of indacaterol 150 and 300 μg (for 14 days) were consistent with moderate systemic accumulation at steady state after repeated once-daily inhalation in healthy Chinese volunteers.

Item Type: Article
Keywords: Chinese population Healthy volunteers Indacaterol Pharmacokinetics
Date Deposited: 25 Nov 2017 00:45
Last Modified: 25 Jan 2019 00:46
URI: https://oak.novartis.com/id/eprint/8493

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.